SIGY (Sigyn Therapeutics) OCF Margin %: 0.00% (As of Sep. 2025)


What is Sigyn Therapeutics OCF Margin %?

Sigyn Therapeutics SIGY +22.62% OCF Margin % is 0.00% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Sigyn Therapeutics ranks worse than 104821.7% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Sigyn Therapeutics's Cash Flow from Operations for the three months ended in Sep. 2025 was $-0.20 Mil. Sigyn Therapeutics's Revenue for the three months ended in Sep. 2025 was $0.00 Mil. Therefore, Sigyn Therapeutics's OCF Margin % for the quarter that ended in Sep. 2025 was 0.00%.

As of today, Sigyn Therapeutics's current OCF Yield % is -1,298.61%.

The historical rank and industry rank for Sigyn Therapeutics's OCF Margin % or its related term are showing as below:


During the past 11 years, the highest OCF Margin % of Sigyn Therapeutics was -19.29%. The lowest was -1052.63%. And the median was -561.07%.

SIGY's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Sigyn Therapeutics OCF Margin % Related Terms

Sigyn Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Sigyn Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sigyn Therapeutics OCF Margin % Chart

Sigyn Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sigyn Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sigyn Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Sigyn Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-0.872/0
= %

Sigyn Therapeutics's OCF Margin for the quarter that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-0.199/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Sigyn Therapeutics (SIGY) has a OCF Margin % of 0.00% as of Sep. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sigyn Therapeutics and its competitors. According to the industry distribution chart, Sigyn Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry.
Is Sigyn Therapeutics' OCF Margin % too high?
Sigyn Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Sigyn Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Sigyn Therapeutics' OCF Margin % compare to RGBP and ENDV?
According to the Biotechnology industry distribution chart, Sigyn Therapeutics ranks #999999 out of 954 companies for OCF Margin %. This places Sigyn Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sigyn Therapeutics and its competitors. Sigyn Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigyn Therapeutics stock overvalued right now?
Sigyn Therapeutics (SIGY) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sigyn Therapeutics (SIGY), the current OCF Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sigyn Therapeutics Business Description

Address 2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.